Subcutaneous Daratumumab vs IV Formulation in Relapsed Multiple Myeloma

The phase III COLUMBA study compared a subcutaneous formulation of daratumumab vs the intravenous form in patients with relapsed or refractory multiple myeloma.

Source: CancerNetwork - March 11, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news